LAUSR

Cisplatin is a chemotherapeutic agent whose therapeutic use is greatly limited by the associated organs' toxicity and particularly, testicular toxicity. Cisplatin‐induced testicular damage reported being mediated through mitochondria‐mediated apoptosis, inflammation, and oxidative stress. Evidence showed that tranilast (TRN) has the ability to restore the oxidative status and modulate TRAIL/caspase‐8 signaling. This led us to hypothesize that TRN could abrogate cisplatin‐induced testicular and epididymal injuries via inhibiting oxidative stress and modulating proliferation and TRAIL/caspase‐8/cJNK signaling. Cisplatin injection induced oligospermia and abnormalities in testicular and epididymal structure along with impaired oxidative status. TRN administration (100 or 300 mg/kg) for 7 days post‐cisplatin injection preserved spermatogenesis and restored testicular and epididymal architecture, but restoration was more so in TRN300 than TRN100. This was in line with the restoration of balanced oxidative status as indicated by the increased total antioxidant capacity, glutathione and superoxide dismutase activity, and the decreased malondialdehyde content in testes (p < 0.05 vs. cisplatin). TRN increased the cell proliferation revealed by the increased expression of proliferating cell nuclear antigen in a dose‐dependent manner (p < 0.05 vs. cisplatin) whereas only TRN300 decreased testicular cJNK, TRAIL, and caspase‐8 expression (p < 0.05 vs. cisplatin). Moreover, TRN dose‐dependently inhibited the pro‐inflammatory transcription factor NF‐kB and the cytokine TNF‐α expressions in testes. In conclusion, TRN300 was more effective than TRN100 in alleviating cisplatin‐induced testicular and epididymal injuries and in enhancing spermatogenesis. This curative effect of TRN might be mediated through its antioxidant and anti‐inflammatory impacts along with its modulatory impact on cJNK/TRAIL/caspase‐8 signaling favoring proliferation rather than apoptosis.